What does this video actually claim?
KimmiG (@kimmi_g88) shares her experience taking a GLP-1 medication for one year, specifically mentioning Zepbound for postpartum weight loss. Her TikTok doesn't make specific medical claims but positions her story within the broader "GLP-1 community" discussing weight management.
The video focuses on personal experience rather than medical advice. She's documenting her journey with tirzepatide (Zepbound's active ingredient) in a postpartum context, which represents a common but understudied use case for these medications.
Is one year on Zepbound medically reasonable?
Yes, and the clinical data supports long-term use. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) followed patients on tirzepatide for 72 weeks, showing sustained weight loss of 20.9% at the highest 15mg dose.
The FDA approved Zepbound for chronic weight management, not short-term use. Most patients who achieve significant results stay on these medications indefinitely because weight regain occurs rapidly after discontinuation.
One year falls well within the safety profile established in clinical trials. The SURMOUNT studies tracked patients for similar durations without major safety concerns beyond expected gastrointestinal side effects.
What about using Zepbound postpartum?
This gets complicated because clinical trials specifically excluded pregnant and breastfeeding women. The postpartum period isn't well-studied for GLP-1 receptor agonists like tirzepatide.
Current prescribing guidelines recommend stopping these medications if you're planning pregnancy or breastfeeding. The timing of when it's safe to restart postpartum isn't clearly established in the research.
Many doctors do prescribe GLP-1s to postpartum patients who aren't breastfeeding, but this represents off-label use beyond the studied populations. KimmiG doesn't specify her breastfeeding status or timing, which would be relevant context.
Does the "GLP-1 community" help or harm?
Social media communities can provide valuable peer support, but they also spread misinformation about dosing, side effects, and expectations. The hashtag #glp1community has become a mixed bag of legitimate experiences and problematic advice.
KimmiG's approach seems relatively responsible. She's sharing personal experience without making medical claims or giving dosing advice.
The risk comes when people use these communities to troubleshoot side effects or adjust medications without medical supervision. The STEP and SURMOUNT trials all involved careful medical monitoring that TikTok can't replace.
What should you actually know about year-long GLP-1 use?
Long-term use is the expectation, not the exception. These aren't quick-fix medications but chronic disease treatments requiring ongoing medical supervision.
The SELECT trial (Lincoff et al., NEJM, 2023) followed patients on semaglutide for over three years, showing sustained cardiovascular benefits beyond weight loss. This suggests these medications work best as long-term interventions.
Side effects typically improve after the first few months, but about 10-15% of patients discontinue due to gastrointestinal issues. Regular check-ins with healthcare providers remain essential throughout treatment.